剂量,第九因子活性水平和出血概率之间的关系 rIX-FP 血友病B的预防:一次重复的时间到事件分析
Sjoerd F Koopman1, Marjon H Cnossen2, Ron A A Mathot1
1Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Clinical pharmacology and therapeutics
|May 19, 2025
概括
延长半衰期因子IX (EHL-FIX) 的药理学导向剂量有助于管理B型血友病. 准20 IU/dL最低FIX活性水平显著减少出血事件,目标是每年零出血.
科学领域:
- 血液学 血液学 血液学
- 药理动力学和药理动力学
- 临床试验 临床试验
背景情况:
- 血友病B的治疗依赖于因子IX (FIX) 替代疗法.
- 延长半衰期的XIX因子 (EHL-FIX) 缩剂可以改善FIX暴露.
- 个性化剂量对于有效的血友病B管理至关重要.
研究的目的:
- 为了分析剂量,FIX活性水平和B型血友病患者的出血之间的关系.
- 评估重组聚变蛋白与专蛋白 (rIX-FP) 结合凝血因子IX的疗效.
- 为了确定最佳的目标FIX活动水平以减少出血.
主要方法:
- 结合了五项临床试验的数据,涉及B型血友病患者.
- 使用参数重复时间到事件 (RTTE) 模型来分析出血概率.
- 包括来自114名患者的2,493个FIX活动水平和514次出血.
主要成果:
- 观察到基线出血率为7.3次/年,FIX活性为零.
- 在FIX活性12 IU/dL时,出血概率降低了50%.
- 针对20 IU/dL的FIX活动最低值,导致年平均出血率 (ABR) 为零.
结论:
- 考虑出血倾向和其他因素的个性化FIX活动目标是必不可少的.
- EHL-FIX缩物rIX-FP在减少出血事件方面表现出有效性.
- 准20 IU/dL的FIX活动水平的值与血友病B的零中位ABR有关.
相关概念视频
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
256
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
256
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
857
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
857
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
409
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
409
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K


